CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid Tumors
April 08, 2024 08:00 ET
|
CytomX Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced the...
CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
April 03, 2024 08:00 ET
|
CytomX Therapeutics Inc.
- Achievement of latest clinical candidate triggers additional $5 million milestone payment to CytomX and is the third milestone achieved in the collaboration to date - - CytomX-retains US...
CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors
March 21, 2024 08:00 ET
|
CytomX Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced the...
CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
March 18, 2024 08:00 ET
|
CytomX Therapeutics Inc.
- Initiation of GLP toxicology study for the first clinical candidate in the collaboration triggers a $5 million milestone payment to CytomX - - Program is one of several ongoing collaboration...
CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update
March 11, 2024 16:10 ET
|
CytomX Therapeutics Inc.
- CX-904 (EGFRxCD3 T-cell engager) initial Phase 1a dose escalation data in solid tumors anticipated in the 2nd half of 2024 - - CX-2051 (EpCAM ADC) Phase 1 clinical study initiation in solid tumors,...
CytomX Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024
March 04, 2024 08:00 ET
|
CytomX Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that...
CytomX Therapeutics to Present at Upcoming March Investor Conferences
February 27, 2024 08:00 ET
|
CytomX Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that...
CytomX Therapeutics Announces FDA Clearance of IND Applications for CX-2051, a Probody® Antibody Drug Conjugate (ADC) Targeting EpCAM and CX-801, a Conditionally Activated Interferon Alpha-2b
January 24, 2024 08:00 ET
|
CytomX Therapeutics Inc.
- Initiation of CX-2051 Phase 1 clinical study in EpCAM positive tumors including colorectal cancer anticipated in 1H 2024 - - Initiation of CX-801 Phase 1 clinical study in solid tumors including...
CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Conference
January 12, 2024 08:00 ET
|
CytomX Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 12, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that...
CytomX Therapeutics Outlines 2024 Company Priorities and Milestones
January 04, 2024 08:00 ET
|
CytomX Therapeutics Inc.
- CX-904 (EGFRxCD3 T-cell engager) initial Phase 1a dose escalation data anticipated in the 2nd half of 2024 - - IND application filed for conditionally activated EpCAM-directed ADC (CX-2051) with...